Radiation oncology firm Sirtex Medical said it has crossed a milestone on its path to apply for drug registration for its SIR-Spheres yttrium-90 microspheres for treating liver cancer.
Sirtext and its partner China Grand Pharmaceutical said that they have received approval from the National Medical Products Administration in China to file a new drug application (NDA) in the country.
Receiving final approval of the NDA will enable Sirtex to enter the Chinese market, according to the firm.
SIR-Spheres yttrium-90 microspheres are used to treat patients with liver cancer, Sirtex said.
